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A retrospective review of adenoviral infection in pediatric liver transplant recipients was done 
at Children's Hospital of Pittsburgh to define its epidemiology and clinical importance. Medical 
records of patients with adenovirus were reviewed and data collected regarding clinical course, 
microbiologic studies, biopsy results, immunosuppression, concurrent infections, and outcome. 
Of 484 liver transplant recipients, 49 had 53 episodes of adenoviral infection. The most common 
sites of adenoviral infection were the liver, lung, and gastrointestinal tract. Serotypes 1, 2, and 5 
were recovered most often; type 5 was commonly associated with hepatitis. Invasive adenoviral 
infection occurred in 20 children, leading to death in 9. Median time from transplantation until 
isolation of adenovirus was 25.5 days. This timing suggests either reactivation or donor-asso-
ciated transmission. Prospective studies using molecular epidemiologic techniques will be help-
ful in evaluating transmission patterns of adenovirus in this population. 
Orthotopic liver transplantation (OL T) is done with in-
creasing frequency in the pediatric population for a variety of 
hepatic disorders. Infectious complications are a major 
source of morbidity and mortality for these patients. Cyto-
megalovirus (CMV) and Epstein Barr virus have been well 
documented as major pathogens after transplantation [1,2]. 
Although adenoviral infection has been previously identified 
as an important cause of hepatitis after OL T in children [3-
7]. analysis has been limited by the small number of affected 
patients in each report. An apparent increase in adenoviral 
infections among pediatric liver transplant patients at the 
Children's Hospital of Pittsburgh led us to review our experi-
ence with this infection. 
Methods 
Pediatric liver transplant recipients with adenovirus isolated 
from one or more sites were identified through the virology labo-
ratory records between I January 1982 and 30 November 1989. 
Medical records of these patients were systematically reviewed 
and data collected regarding clinical course, microbiologic 
studies, biopsy results, immunosuppression, concurrent infec-
tions, and outcome using standardized definitions. Adenoviral 
isolates during the same time period from nontransplant pa-
tients were recorded by date, source of isolate, and serotype. 
Viral studies. Surveillance viral cultures ofrespiratory secre-
tions. urine, and buffy coat were obtained every other week for 
the first 2 months after liver transplantation from 1985 to 1988. 
These same studies were routinely sent as part of an evaluation 
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of fever, along with cultures of stooL liver biopsy. and bron-
choalveolar lavage (BAL) fluid when clinically indicated. Liver 
biopsies were routinely sent for viral culture regardless of clini-
cal status after June 1985. Specimens were inoculated into sin-
gle tubes of African green monkey kidney. rhesus monkey kid-
ney. HEp-2 cells and human foreskin fibroblasts. Starting in 
May 1987, human neonatal kidney cells were also used. Cul-
tures were maintained for 2 weeks with the exception of human 
foreskin fibroblasts, which were observed for 4 weeks. Through-
out the study, adenovirus was identified by its cytopathic effect. 
Beginning in 1988, an adenoviral EIA (Adenoclone; Cambridge 
Bioscience, Worcester MA) was also used to confirm the diagno-
sis. At least one isolate from each patient was sent to the Alle-
gheny County Health Department for serotyping using adeno-
viral antisera to types 1-8 and 19 (Centers for Disease Control, 
Atlanta). 
Pathologic studies. Pathologic specimens included tissue 
from biopsies, BAL fluid, and autopsy specimens. Touch prepa-
ration of tissues and frozen and permanent sections were pro-
cessed for routine histologic studies. Biopsy and autopsy speci-
mens were stained using an avidin-peroxidase method with 
monoclonal anti-adenovirus antibody (MA805) and anti-CMV 
antibody (MA81 0), as previously described [3]. Histologic iden-
tification of adenovirus was made by finding typical inclusion 
bodies. positive antibody stain, or electron microscopic evi-
dence consistent with adenovirus in the tissue. 
Definitions of clinical illness. Clinical episodes during which 
adenovirus was recovered from culture were classified as defi-
nite, probable, possible. or indeterminate for adenoviral disease 
depending on the success of demonstrating tissue damage, viral 
inclusions, or evidence of concurrent infection. Symptomatic 
infection was defined as one in which at least some of the pa-
tient's symptoms could be (definitely or probably) ascribed to 
adenovirus. Invasive infections were defined as those with evi-
dence of organ involvement. Fever was considered a tempera-
ture >38.0°C. 
A diarrheal illness was defined as a new report of diarrhea (at 
least six liquid stools a day) for?2 days (consecutive). Adenovi-
rus was considered to be the probable cause of the illness if 
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diarrhea was accompanied by a positive stool culture in the ab-
sence of other recognized pathogens. Adenovirus was consid-
ered to be the possible cause when the stool was positive but 
concurrent enteri<; pathogens were also identified. 
Pneumonia was diagnosed when fever, new or worsening 
lower respiratory symptoms, or hypoxemia accompanied radio-
graphic pulmonary changes. Adenovirus was considered to be 
the definite cause of pneumonia when isolated from BAL fluid 
or lung biopsy specimen. Probable adenoviral pneumonia was 
diagnosed if the organism was isolated from upper respiratory 
tract secretions in the absence of concurrent pathogens. Other-
wise, the illness was classified as possible adenoviral pneumonia 
(mixed infection) or indeterminate. 
Hepatitis was diagnosed by the presence of fever. elevated 
transaminase levek and characteristic histopathology. Definite 
adenoviral hepatitis was defined histologically by the finding of 
adenoviral inclusions, positive antibody stain or positive elec-
tron microscopy. In addition, suggestive histopathology (con-
sisting of microabscesses and cell dropout without inclusions 
[3]) was also considered definite adenoviral hepatitis if the cul-
ture from the liver was positive. Diagnosis of probable adeno-
viral hepatitis was made when the liver culture was positive but 
histopathology was not confirmatory. Possible adenoviral hepati-
tis was the classification applied to patients when histopathology 
of the liver was suggestive and adenovirus was isolated from a 
site other than the liver. Indeterminate adenoviral hepatitis was 
defined when adenovirus was isolated from the liver but anti-
body stains were negative and concurrent infection was present. 
Concurrent bacterial or fungal infections were identified 
when organisms were isolated from a normally sterile site within 
I week of the adenoviral isolation. Contaminants were excluded 
by the lack of clinical correlation, negative repeat cultures be-
fore therapy, or both. Viral infections within 2 weeks of the 
adenoviral isolate were also considered concurrent infections. 
Immunosuppression. Immunosuppressive regimens varied 
slightly over the course of the study. All children received cyclo-
sporine and steroids as previously described [7]. In addition, 
azathioprine was given to 17 children. Suspected or proven mild 
to moderate rejection was treated with steroid augmentation. 
Steroid-resistant rejection was treated with a cycle ofOKT3 (a 
murine monoclonal antibody to T lymphocytes). 
Statistical methods. Yates's corrected X2 test was used for 
analysis of continuous variables, and Student's t test was used 
for categorical variables. Fisher's exact test was used for small 
samples. P < .05 was considered significant. and .05 < P:;;; .1 
was considered indicative of a trend. 
Results 
Patient population. During the study period, 484 chil-
dren underwent 656 OL Ts. Fifty children had adenovirus 
isolated from one or more sites. The virus was found preoper-
atively in one child on a surveillance culture, thereby elimi-
nating him from analysis. Of the remaining children, 20 were 
boys and 29 were girls. Ages at the time ofOL T ranged from 
0.8 to 17.2 years (median. 3.0) and were similar to the ages 
of all children undergoing OL T. Biliary atresia was the most 
common (71 %) disorder leading to transplantation. 
Fifty-three episodes of adenoviral infection occurred in 49 
patients. Four children had two different serotypes isolated. 
In one patient the different strains were isolated only I day 
apart from stool and urine. The other three patients had tem-
porally separate episodes 8, 30, and 255 days after the initial 
infection. 
Timing. The median time of adenoviral isolation was 
25.5 days after liver transplantation (range, 4-888). Only 
four episodes of the infections occurred >3 months after 
transplantation and none of these were invasive. Severe in-
fections, such as hepatitis or pneumonia, occurred within the 
first 50 days except in two cases, 64 and 69 days after trans-
plantation. The latter patient had concurrent rejection and 
posttransplant lymphoproliferative disease. Apparent clus-
ters of adenoviral in fection occurred at several times, but not 
all isolates from each cluster were of the same serotype. No 
patient shared the same or adjacent rooms, and none of the 
children shared primary nurses. 
Serotypes and sites of isolation. Table I lists the adeno-
viral serotypes and sites of isolation in the OLT patients as 
well as adenoviral isolates from 85 non-OL T patients during 
the study period. Two OL T patients had adenoviral strains 
that were not typeable against available antisera, and one 
patient's isolate was not available for serotyping. Serotypes I 
and 2 were found commonly among both groups of patients. 
However, the study patients had a high prevalence of adeno-
virus type 5, while the non-OL T patients were often found to 
have disease caused by types 3 and 8. No apparent temporal 
relationship was noted between isolates recovered from OL T 
recipients and those from the community. 
Urine was the most common site of adenoviral isolation; 
23 infectious episodes were documented in 20 patients. Signs 
and symptoms of disease accompanied II ofthe 23 episodes. 
Two children had hemorrhagic cystitis. Nine had adenovirus 
isolated from other sites with symptoms reflective of their 
primary area of involvement. Three episodes of adenovirus 
associated with concurrent infection were classified as inde-
terminate. Eight children with only a urine isolate had asymp-
tomatic shedding. 
Twenty-one children had adenovirus isolated from respira-
tory secretions: 19 from throat or nasopharyngeal swabs and 
3 from BAL fluid in children with severe respiratory illness 
and high fever. Two of these 3 children died with adenoviral 
infection as a contributing factor. Five children had probable 
and 2 had possible adenoviral pneumonia (table 2). The rest 
had upper respiratory infections (2), extrapulmonary symp-
toms (3), or no symptoms. 
Sixteen adenoviral episodes involved the liver. Of these 
children, 14 had definite adenoviral hepatitis (table 2) occur-
ring 15-69 days after transplantation (mean, 27). All had 
fevers >40.0°C. The number of febrile days ranged from 6 to 
44 (mean, 16). Eight children with hepatitis recovered, 4 
without loss of their graft. Immunosuppression had been de-
creased in 3. Four surviving children required retransplanta-
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Table 1. Serotypes and source of adenoviral isolates in orthotopic liver transplant recipients and 
others during 1982-1989. 
Total 
episodes Nontransplant 
Source of adenovirus with patient with 
serotype. serotype. 
Serotype Urine Throat BAL Liver Stool Blood no. (C[) no. (%) 
I 6 2 0 3 5 0 12 (22) 16 (19) 
2 6 10 3 4 4 3 18 (34) 19 (22) 
3 0 0 0 0 0 0 0 16 (19) 
4 0 0 0 0 2 2 (4) 2 (2) 
5 7 5 0 9 3 3 16 (30) 4 (5) 
6 0 0 0 0 0 I (2) 0 
7 0 I 0 () 0 0 1 (2) 2 (2) 
g 0 0 0 0 0 0 0 13 (15) 
19 0 0 0 0 0 0 0 2 (2) 
Not 1-7a, 
R. or 19 2 0 0 0 0 U 2 (4) 2 (2) 
Not typed 1 I (2) 9 (II) 
Total 23 19 3 16 12 8 53(100) 77 (99)* 
NOTE. BAL. bronchoalveolar lavage. 
* Only 99% of patients are accounted for because of rounding errors. 
tion; fever resolved immediately in each. Six children died. 
Adenovirus contributed to the death in 5 patients, three of 
whom died during retransplantation. 
Stool cultures were positive for adenovirus in 13 children; 
9 were symptomatic. Seven children had gastroenteritis with-
out other identifiable pathogens. One child had concurrent 
CMV hepatitis. while another child had concurrent Pseudo-
monas bacteremia. 
Eight children had adenovirus isolated from buffy coat 
specimens. This was the sole site of isolation in only two 
patients. In the rest it was a confirmatory culture in children 
with pneumonia or hepatitis. 
S)mptoms. Of the 53 episodes of adenoviral infection, 
34 were associated with symptomatic illnesses; 20 patients 
had invasive disease (table 2). Fifteen children were asymp-
tomatic, and 6 patients were classified as indeterminate. Eval-
uation of risk factors for symptomatic and invasive disease 
was done. Thirteen of20 children with invasive disease com-
pared with 3 of28 with noninvasive disease had adenovirus 
isolated from more than one body site (P < .001). 
Serotype 5 was associated with symptomatic disease more 
often than other serotypes (P < .05). Fifteen of 17 episodes 
of adenoviral infection with serotype 5 were symptomatic; 
10 were invasive. 
The use of OKT3 showed a trend toward an association 
with severe infection. OKT3 was used in 12 (60%) of 20 
patients with invasive disease compared with 9 (32%) of 28 
without invasive disease (P = .1). Other factors including 
age, time to infection, use of azathioprine, concurrent CMV 
infection, and number of rejection episodes were not signifi-
cant risk factors for symptomatic or invasive disease. 
Discussion 
The incidence of adenoviral infection after pediatric OL T 
at our institution was 10.1 %. Although this study was retro-
spective, viral cultures were submitted for all patients with 
significant fevers and illnesses. Accordingly, serious adeno-
viral infections should not have been overlooked. The me-
dian time from OLT until adenoviral infection was 25.5 
days, with all symptomatic disease occurring within the first 
3 months. Nonetheless, one of our recent transplant recipi-
ents presented with a rapidly fatal adenoviral hepatitis 6 
months after OL T. This child was heavily immunosup-
pressed, providing the probable risk factor for severe late in-
fection. 
Serotypes I, 2, and 5 were most common, with serotype 5 
causing most of the cases of hepatitis. Serotype 5 is a recog-
nized cause of hepatitis in both immunocompromised and 
normal hosts [8, 9]. An earlier review of adenoviral hepatitis 
from our institution implicated only serotype 5 [3]. In this 
series we found hepatitis caused by serotypes I and 2 as well. 
The most common invasive disease associated with adeno-
virus in our population was hepatitis. This contrasts with 
bone marrow transplant and renal transplant recipients, in 
whom the most common expressions of adenoviral infection 
were pneumonia and hemorrhagic cystitis. respectively [8. 
10, II]. Solid organ transplant recipients are known to have 
a propensity to develop infections at or near the site of the 
transplanted organ. It is hypothesized that allograft reactions 
such as graft-versus-host or host-versus-graft disease may 
make the organ a susceptible target for infection [2]. Alterna-
tively, the donor organ may be the source of the viral infec-
tion and thus the site of initial activity. 
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Table 2. Orthotopic liver transplant (OL T) patients with invasive adenoviral infection. 
Disease. patient No. of days Sites Concurrent 
no. Serotype after OLT infected infections Intervention Outcome 
Hepatitis 
1 5 17 Liver None Second OLT Survived: improved after second OL T 
2 26 Blood, liver, CMV pneumonia Decreased Survived: severely ill, slow gradual 
urine and esophagitis immunosuppression improvement 
3 5 14 Liver. urine None Decreased Survived: mild hepatitis. self-limited illness 
immunosuppression 
4 5 18 Blood, liver. Abdominal Decreased Died: severe disseminated disease 
resp abscess immunosuppression 
(autopsy) 
5 5 45 Liver Klebsiella None Died: severe hepatitis and rejection; died 
bacteremia during second OL T 
6 5 23 Liver, stool AV type 2 in Decreased Survived: improved after second OLT 
urine immunosuppression, 
second OLT 
7 24 Liver PTLD IVIG, second OLT Died: severe illness; died during second 
(autopsy) OLT 
8 69 Liver, resp, PTLD, fungal Decreased Died: hemodynamic instability 
urine wound immunosuppression 
infection 
9 5 32 Liver None Decreased Survived: limited illness that improved by 
immunosuppression 10 days 
10 44 Liver None None Survived: self-limited illness 
II 15 Bile, liver, Bacterial Second OLT Survived: severe illness that resolved after 
pleura cholangitis second OLT 
12 2 17 Blood, liver, CnS bacteremia Decreased Survived: biphasic with fevers and A V+ 
resp, immunosuppression, diarrhea; fever resolved by I week, then 
stool. second OLT progressive severe disease, followed by 




13 5 20 Blood. liver. None Decreased Died: severe illness with respiratory distress 
resp, immunosuppression and hepatitis 
urine 
14 2 16 Blood, liver, None Decreased Died: progressive disseminated disease 




15 2 9 SAL fluid, Rotavirus Decreased Survived: severe 16-day illness that 
resp immunosuppression required mechanical ventilation 
16 2 4 BAL fluid, CnS bacteremia Decreased Died: progressive respiratory illness leading 
resp, immunosuppression to death in 10 days 
stool 
17 2 13 BAL fluid None Decreased Died: progressive respiratory illness leading 
immunosuppression to death in II days 
Probable 
pneumonia 
18 2 14 Resp CnS line None Survived: self-limited illness 
infection 
19 4 64 Blood, resp None Decreased Died: severe disseminated illness, leading 
immunosuppression to death in 9 days 
20 5 17 Resp (,MV hepatitis, Decreased Died: progressive respiratory illness after 
probable CMV immunosuppression disseminated CMV disease, leading to 
pneumonia death in 23 days 
NOTE. CMV. cytomegalovirus: resp. respiratory system; A V. adenovirus; PTLD, posttransplant Iymphoproliferative disease: IVIG, intravenous immuno-
globulin: CnS, coagulase-negative staphylococci: BAL, bronchoalveolar lavage. 
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Review of potential risk factors suggested that neither 
CMV infection, number of rejection episodes, nor azathio-
prine use correlated with severe disease. A trend was seen 
between OKT3 use and invasive adenoviral infection. The 
potential significance ofOKT3 is supported by other studies 
ofliver transplant recipients, which showed an increased risk 
of invasive viral disease after its use [7]. 
The usual occurrence of serious adenoviral infections 
within the first several months after transplantation has been 
noted by others [8, 10-12]. This timing of adenoviral infec-
tion suggests reactivation of latent virus, donor organ-asso-
ciated transmission, or nosocomial transmission. Adenovirus 
has been shown to have a capacity for latency, so both donor 
transmission and reactivation are possible. Shields et al. [8] 
suggested reactivation as the most likely mode of transmis-
sion of adenovirus in bone marrow transplant patients, while 
Koneru et al. [13] found the most severe disease in liver 
transplant recipients who were seronegative for adenovirus 
before transplant. Donor serology was positive in five of six 
evaluated patients, suggesting donor transmission as the 
likely source. A recent case report also suggested donor 
transmission but implicated acute viremia in the donor at the 
time of his death [6]. Donor transmission of other infections 
such as CMV and Epstein-Barr virus has been documented 
[14, IS], demonstrating biologic plausibility for this mode of 
transmission. 
Nosocomial acquisition of adenoviral infection is also a 
consideration, as several patients with the same strains were 
found temporally clustered. Although patients did not share 
primary nurses or rooms, the physician team was identical 
for all transplant recipients hospitalized at the same time. In 
addition, nurses commonly cross-cover on a floor, and a com-
munal playroom is available. Accordingly, nosocomial 
transmission may account for some of the observed infec-
tions. Prospective studies using molecular epidemiologic 
techniques may be able to clarity the role of donor transmis-
sion for adenovirus in the future. 
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